Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Delayed Nasdaq  -  04:00 2022-11-28 pm EST
15.54 USD   -2.45%
11/09Deciphera Pharmaceuticals, Inc. to Participate in Upcoming November 2022 Investor Conferences
AQ
11/08Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
BU
11/03Transcript : Deciphera Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 03, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology Congress 2022

09/10/2022 | 09:00am EST

Deciphera Pharmaceuticals, Inc. announced positive initial data from the single agent dose escalation portion of the Phase 1 study of DCC-3116, the Company's first-in-class, potent, and selective small molecule switch-control kinase inhibitor of ULK1/2, in patients with advanced or metastatic tumors with a mutant RAS or RAF gene. Results from the study were presented in an oral presentation as a Proffered Paper titled “Initial monotherapy results of a phase 1 first-in-human study of ULK1/2 inhibitor DCC-3116 alone and in combination with MAPK pathway inhibition” at the ESMO Congress 2022. As of June 9, 2022, 18 patients with locally advanced or metastatic cancer with a RAF or RAS mutation were enrolled across four cohorts dosed with DCC-3116 twice daily (BID): 50 mg BID (n=3); 100 mg BID (n=4); 200 mg BID (n=7); and 300 mg BID (n=4).

The median number of prior anti-cancer regimens was three (range 1-10). The most common cancer types were colorectal (56%) and pancreatic (28%) and patients had KRAS (83%) and BRAF (17%) mutations. The results of the primary objectives of safety and tolerability as well as the additional objectives of pharmacokinetics, pharmacodynamics, and anti-tumor activity are summarized below: Treatment with DCC-3116 was well tolerated and most treatment-emergent adverse events (TEAEs) were Grade 1/2; the most common (=15%) TEAEs regardless of relatedness reported (all grades) were: fatigue (39%), dehydration (22%), alanine transaminase (ALT) increases (17%), anemia (17%), aspartate transaminase (AST) increases (17%), decreased appetite (17%), hyponatremia (17%), nausea (17%), and vomiting (17%).

No dose-limiting toxicities or treatment-related serious adverse events were observed with DCC-3116; two asymptomatic, reversible Grade 3 alanine transaminase increases that led to dose interruption and reduction were reported as treatment-related.


ę S&P Capital IQ 2022
All news about DECIPHERA PHARMACEUTICALS, INC.
11/09Deciphera Pharmaceuticals, Inc. to Participate in Upcoming November 2022 Investor Confe..
AQ
11/08Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
BU
11/03Transcript : Deciphera Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 03, ..
CI
11/03Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Reports Q3 Revenue $32.2M, vs. Street E..
MT
11/03Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Reports Q3 Loss $-0.55, vs. Street Est ..
MT
11/03DECIPHERA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Cond..
AQ
11/03Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results
BU
11/03Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine..
CI
10/27Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Ho..
BU
09/27Stifel Adjusts Price Target on Deciphera Pharmaceuticals to $18 From $11, Reiterates Ho..
MT
More news
Analyst Recommendations on DECIPHERA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 132 M - -
Net income 2022 -179 M - -
Net cash 2022 89,3 M - -
P/E ratio 2022 -6,22x
Yield 2022 -
Capitalization 1 050 M 1 050 M -
EV / Sales 2022 7,26x
EV / Sales 2023 5,24x
Nbr of Employees 280
Free-Float 72,7%
Chart DECIPHERA PHARMACEUTICALS, INC.
Duration : Period :
Deciphera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DECIPHERA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 15,54 $
Average target price 19,61 $
Spread / Average Target 26,2%
EPS Revisions
Managers and Directors
Steven L. Hoerter President & Chief Executive Officer
Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP
James A. Bristol Chairman
Daniel L. Flynn President, Chief Executive Officer & Director
Stephen B. Ruddy Chief Technical Officer & SVP
Sector and Competitors
1st jan.Capi. (M$)
DECIPHERA PHARMACEUTICALS, INC.59.06%1 050
VERTEX PHARMACEUTICALS43.58%80 935
REGENERON PHARMACEUTICALS, INC.16.58%79 191
BIONTECH SE-37.36%39 245
WUXI APPTEC CO., LTD.-35.85%30 708
GENMAB A/S22.93%29 471